Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Phase 3 Idiopathic Pulmonary Fibrosis Trials

8 Phase 3 trials for Idiopathic Pulmonary Fibrosis. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT05422222

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at...

Sponsor: Vertex Pharmaceuticals IncorporatedEnrolling: 21020 locations
RECRUITINGPhase 3NCT07299695

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to...

Sponsor: Argyrios TzouvelekisEnrolling: 1961 location
RECRUITINGPhase 3NCT06238622

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a...

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a...

Sponsor: Boehringer IngelheimEnrolling: 170020 locations
RECRUITINGPhase 3NCT05075161

Pirfenidone to Prevent Fibrosis in Ards.

Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury and a major cause of Intensive Care Unit (ICU) admission worldwide. Despite a large number of...

Sponsor: Università Vita-Salute San RaffaeleEnrolling: 13017 locations
RECRUITINGPhase 3NCT05677971

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring...

The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening...

Sponsor: TakedaEnrolling: 16020 locations
RECRUITINGPhase 3NCT06996951

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective...

The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain...

Sponsor: Indiana UniversityEnrolling: 641 location
RECRUITINGPhase 3NCT04965298

Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

IPF is a progressive scarring lung condition causing coughing and breathlessness. IPF patients often have reflux disease meaning stomach acid may be breathed into the lungs,...

Sponsor: Norfolk and Norwich University Hospitals NHS Foundation TrustEnrolling: 29820 locations
RECRUITINGPhase 3NCT05943535

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Sponsor: United TherapeuticsEnrolling: 69820 locations